Villar Alvarez Felipe, Méndez Bailón Manuel, de Miguel Díez Javier
Servicio de Neumología, Fundación Jiménez Díaz - CAPIO, Madrid, España.
Arch Bronconeumol. 2009 Aug;45(8):387-93. doi: 10.1016/j.arbres.2008.05.011. Epub 2009 Jul 12.
Chronic obstructive pulmonary disease (COPD) is commonly associated with heart failure. Individuals with COPD have a 4.5-fold greater risk of developing heart failure than those without. The sensitivity and specificity of clinical judgment in the diagnosis of heart failure in patients with COPD can be enhanced by biological markers such as B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide. Correct interpretation of imaging results (mainly echocardiographic findings) and lung function tests can also help establish the co-occurrence of both conditions. There is little evidence on the management of patients with COPD and heart failure, although treatment of COPD undeniably affects the clinical course of patients with heart failure and viceversa.
慢性阻塞性肺疾病（COPD）常与心力衰竭相关。患有COPD的个体发生心力衰竭的风险比未患COPD的个体高4.5倍。B型利钠肽和N末端B型利钠肽原等生物标志物可提高COPD患者心力衰竭诊断中临床判断的敏感性和特异性。正确解读影像学结果（主要是超声心动图检查结果）和肺功能测试也有助于确定这两种疾病是否同时存在。尽管COPD的治疗无疑会影响心力衰竭患者的临床病程，反之亦然，但关于COPD合并心力衰竭患者管理的证据很少。
